Company ProfilePremium

Bluechiip Limited

Company Profile Analysis

Ticker: BCT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bluechiip Limited - Company showcase

Year Founded & Workforce

2003

Bluechiip Limited logo

Bluechiip Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bluechiip Limited Overview

Bluechiip was a Melbourne-based developer of wireless tracking technology for biological samples stored in extreme environments. Its core intellectual property was a MEMS (micro-electro-mechanical systems) resonator tag that contains no electronics. A reader excites the tag and identifies it from its mechanical resonance signature, and it also reads the sample temperature. The company claimed this works from liquid-nitrogen temperatures (about -196°C) to +200°C, through frost, and after autoclaving, gamma sterilisation and centrifugation, where labels, barcodes and conventional RFID struggle. From 2011 to about 2020 Bluechiip operated mainly as an R&D and OEM-licensing company (notably with Labcon North America). From late 2021 it pivoted to direct sales of a branded "Advanced Sample Management Solution" (tagged cryovials, readers and Stream software) to biobanks, pharma and cell-and-gene-therapy labs. Revenue never exceeded about $1m a year. Repeated dilutive raises could not fund the commercial ramp, and the company entered administration in March 2025 and liquidation in mid-2025.


What the company did. The FY2024 Appendix 4E describes the principal activity as developing and commercialising a wireless tracking solution for healthcare and life science, security, defence and manufacturing. The company positioned this as a generational replacement for handwritten and pre-printed labels, linear and 2D barcodes, and chip-based RFID. In practice, nearly all commercial activity from FY2019 onward was in life sciences: cryogenic storage of cells, tissues, blood products, embryos and gametes, and cell-and-gene-therapy (CGT) materials.

Technology. Each Bluechiip tag is a miniature mechanical chip. Because it has no integrated circuit, it tolerates temperature extremes and sterilisation processes that damage silicon RFID. Corporate boilerplate in ASX releases states that the system does not need line of sight, can read through frost, and senses the temperature of each tagged item. That last capability was the key differentiator: an ID plus a per-sample temperature record in cryogenic storage. Management repeatedly described this in releases as the only system offering ID with sample temperature in cryogenic environments.

Business model and revenue model. The model evolved through three phases:

  1. R&D / co-development (2003 to about 2017). Funded largely by equity and the Australian R&D Tax Incentive (RDTI), with little or no ordinary revenue. The FY2011 report showed no revenue from ordinary activities.

  2. OEM supply and licensing (about 2017 to 2021). The anchor was a three-year supply agreement with Labcon North America that management valued at more than US$11.6m (about A$15.9m) when FY2019 results were reported. FY2019 revenue reached a record $1.025m. The Labcon relationship later ended in a settlement involving product returns and a cash payment.

  3. Direct-to-market branded solutions (December quarter 2021 to 2024). Bluechiip launched its own branded Advanced Sample Management Solution into the global biobanking market. In 2022 it registered its own range of storage products, including cryovials. Revenue in this phase came from (a) one-off product sales (readers, tagged consumables, racks and boxes), (b) recurring consumables and annual Stream software licences, (c) engineering services for OEM partners, and (d) licence fees (Fujifilm Irvine Scientific 2021; BioLife Solutions 2024).

Revenue mix (FY2024 Appendix 4E, Note 3):

In FY2024, product and software made up about 95% of revenue. Engineering services collapsed because OEM activity fell. Software licences were not separately broken out from product sales, so the true "subscription" share cannot be isolated. The June 2023 quarterly report noted recurring revenue (consumables, annual Stream licences and additional readers) of about $75k in that quarter, roughly triple the December 2022 quarter.

Value chain position. Bluechiip designed the MEMS tag and reader electronics and outsourced most semiconductor fabrication. A 2023 Supply Chain Resilience Initiative (SCRI) grant was intended to build an in-house micro-electronics fabrication line, but the project was terminated in June 2024. Bluechiip then integrated tags into consumables (cryovials, blood bags or cassettes, CGT bags) and sold readers and software. It sat between component suppliers (MEMS foundries, plastics moulders) and end users (biobanks, pharma, CGT manufacturers, IVF clinics), and also sold to OEM partners who embedded the tag in their own consumables (Labcon, Fujifilm Irvine Scientific, BioLife Solutions).

Customer types and end-markets. Biobanks and biorepositories; global pharmaceutical companies (management disclosed orders from three "top-20" pharma companies by November 2023); cell and gene therapy developers and manufacturers; assisted reproductive technology (IVF) through the Fujifilm Irvine Scientific programme; and research institutes and hospital labs. By June 2023, 14 end-users had ordered across 26 laboratories (FY2022: 10 labs). The December 2024 quarterly report stated sales to 38 laboratories across 18 customers.

Independent characterisation. Bluechiip was a sub-scale, pre-profit deep-tech hardware company with a credible niche technology and a structurally hard go-to-market. Its products required customers to change validated cold-chain workflows and switch consumables, which brought long sales cycles (as management itself acknowledged in the FY2024 commentary), high cost-to-serve, and heavy working-capital needs. At 30 June 2024 inventory was $3.30m, about 6.8 times FY2024 revenue. The company never reached revenue scale to cover a cost base of about $6.7m a year, and it relied on equity raised at progressively lower prices, RDTI refunds and expensive R&D advance loans (16% p.a. in FY2024).

Strategy

Stated strategy (themes from FY2023–FY2024 disclosures, paraphrased).

  1. Direct to market. Move from relying on OEMs to selling the branded Advanced Sample Management Solution directly to pharma, biobanks and CGT developers, with emphasis on North America.

  2. Land and expand to recurring revenue. Win a laboratory, then grow recurring revenue from Bluechiip-enabled consumables, annual Stream licences and extra readers. The CEO said a reasonably sized customer could generate meaningful recurring revenue, though no figure was verified.

  3. Pharma and CGT focus. Target top-20 pharma (three named as customers by November 2023, identities undisclosed) and the CGT bioproduction market, culminating in the BioLife Solutions licence.

  4. Strategic partners for scale. Use OEMs such as Fujifilm Irvine Scientific (ART) and BioLife (CGT packaging) to access global channels without building a large salesforce.

  5. Supply-chain resilience. Build sovereign micro-electronics fabrication capability under the SCRI grant. Abandoned in June 2024.

  6. Path to cash-flow break-even. Grow the customer base to reach cash-flow break-even. Management restated this target in the late-2024 suspension update without a date or revenue threshold.

Medium-term financial targets. None quantified. No revenue, margin or break-even dates were given.

ESG commitments. None disclosed.

Products & Services

All products sat within the single life-science sample-management business. Pricing was not publicly disclosed for any item. Launch years are given where known; otherwise "not disclosed". The product names come from Morningstar's company description; the specifications come from ASX boilerplate and press coverage.

Disposition. All of these assets were sold under the offer the administrator accepted on 17 June 2025.

Product Portfolio

Product / offeringCategoryDescription and capabilitiesTarget customerLaunch / versionPricing

Bluechiip MEMS tag (core IP; "delta" generation used in the Labcon programme)

Core technology

Electronics-free MEMS resonator giving wireless ID plus temperature sensing. Claimed operating range about -196°C to +200°C. Survives autoclaving, gamma irradiation, humidification, centrifugation and frosting. No line of sight needed.

OEM partners; embedded in all Bluechiip consumables

Developed 2003–2011; commercial from about 2017–2019

—

Retrofit Button for CryoVials

Consumable / accessory

Tag housing that retrofits Bluechiip ID and temperature to existing cryovials

Biobanks and labs with legacy inventories

——

Bluechiip-enabled CryoVials

Consumable

Cryogenic storage vials with embedded tag. Company-branded storage products registered in 2022.

Biobanks, pharma, CGT

Branded range from 2022

Not disclosed; source of recurring revenue

CryoVial Box

Storage hardware

Storage box for tagged vials, compatible with box-level reading

Biobanks, pharma

——

CryoTag

Consumable

Tag format for cryogenic sample containers

Labs, biobanks

——

Blood Cassettes

Consumable

Tagged cassettes for blood and cord-blood bag storage

Blood and cord-blood banks

——

Towers / Racks / Frames

Storage hardware

Tagged storage infrastructure for liquid-nitrogen and freezer environments

Biobanks, CGT manufacturers

——

Matchbox Reader

Reader hardware

Desktop single-sample reader

Bench-level lab users

——

Multi-Vial Reader

Reader hardware

Reads many tagged vials at once, such as a full box

High-throughput biobanks

——

Hand-Held Reader

Reader hardware

Portable reader for use at the freezer or dewar

Biobanks, clinics

——

Bluechiip Stream

Software

Sample-management software that records ID, location, temperature history and audit trail. Sold as annual licences.

All end-users

In market by FY2023

Annual licence (amount not disclosed)

Bluechiip Workstation

Integrated system

Workstation integrating reader(s) and software into the sample-handling workflow

Pharma and CGT labs

Launched Jun 2024 at BIO International, San Diego

—

Bluechiip Advanced Sample Management Solution

Solution bundle

Marketing name for the full stack: tagged consumables, readers and Stream

Biobanking, pharma, CGT

Launched Dec quarter 2021

Project-based; not disclosed

ART / IVF system (with Fujifilm Irvine Scientific)

OEM development

Customised, miniaturised MEMS tracking for IVF cryo-storage, giving temperature with ID

IVF clinics, via FISI

Agreement Oct 2021 (two years); commercial launch not disclosed

Licence and development fees

CGT packaging integration (with BioLife Solutions)

OEM licence

Exclusive rights for BioLife to integrate Bluechiip tech into its CGT packaging (e.g., cryo-storage cases and bags)

CGT manufacturers, via BioLife

Signed Dec quarter 2024

Initial project value up to US$750k; licence fee received in the Dec 2024 quarter

Engineering services

Service

Custom engineering and integration for OEM partners

OEMs

Ongoing; $425k FY2023, $25.6k FY2024

Fee for service

“—” = not publicly disclosed.

Financial Narrative

Source and coverage. FY2023 and FY2024 come from the FY2024 Appendix 4E (unaudited; FY2023 comparatives as previously reported). FY2022 balance-sheet items come from opening balances in that document. FY2019 is cited in the commentary for context. FY2025 was never reported: the company was suspended, entered administration before lodging, and never lodged FY2024 audited accounts or any FY2025 report.

Income statement

Derivation note: EBIT equals pre-tax loss plus finance costs (it includes interest income of $6.8k in FY2023 and $6.2k in FY2024). EBIT plus depreciation reconciles exactly to the company's reported "Operating EBITDA" in both years.

Margins and growth

Revenue CAGR. FY2019 revenue was $1.025m (Biotech Daily) and FY2024 revenue was $0.485m, which gives a five-year CAGR of about -13.9%. The business shrank over the period in which it was supposed to commercialise.

Balance sheet

Notes on the balance sheet.

Inventory: Inventory of $3.30m (raw materials $2.06m net; finished goods $1.24m net) was the largest asset. It included products returned by Labcon, at an adjusted original cost of about US$783k.

Deferred revenue: The $1.80m Labcon contract liability (the US$850k settlement cash plus deferred settlement revenue from the returned products) was effectively a non-cash obligation to give Labcon up to US$1.35m in credits on future purchases. The $407k unspent SCRI grant became a cash refund liability ($448k incl. GST invoiced 30 July 2024) once the project was terminated.

Intangibles: No capitalised development costs or acquired intangibles: all R&D and patent costs were expensed. On liquidation, the patent portfolio therefore had no book value, though it presumably formed part of the assets sold.

Cash flow

The FY2022 RDTI figure of $1.1m relates to the FY2021 refund received on 29 June 2022, per the ASX release of that date.

Ratios

ROE and ROA use year-end balances because average balances are not available for all years. Ratios derived from negative earnings are shown for completeness but are economically "not meaningful".

ROIC: is not meaningful (negative NOPAT on a small, mostly inventory-funded capital base).

Net debt/EBITDA: is not meaningful (negative EBITDA).

Cash conversion cycle: A conventional calculation gives several thousand days, because inventory is enormous relative to cost of sales and "trade payables" include opex suppliers. The meaningful takeaway is that inventory equalled about 18 years of FY2024 cost of sales. Much of it was effectively unsaleable at book value, as the liquidation outcome later confirmed.

Commentary on trends, inflections and drivers

Revenue. Revenue peaked at about $1.0m in FY2019 under the Labcon OEM agreement. The Labcon relationship ended in a settlement involving the full return of previously sold delta tags. The pivot to direct sales from the December 2021 quarter produced a growing but tiny base of end-users (10 labs in FY2022, 26 labs by June 2023, 38 labs across 18 customers by December 2024). FY2024 revenue fell 47% to $485k because engineering-services income almost disappeared as OEM activity dried up, which outweighed 15% growth in product and software sales. Management attributed the weakness to prolonged sales cycles and adverse economic conditions, mainly in the United States. In a May 2024 interview the CEO described the latest quarter as very light.

Costs. The cost base rose rather than fell as revenue declined. Employee costs grew 16% in FY2024 to $4.15m because of the US sales build-out. Finance costs quadrupled to $126k because the RDTI advance was drawn earlier and at 16% interest. External R&D fell 59% as the company moved from development to commercialisation, which also reduced the RDTI refund it could claim. That created a feedback loop: less R&D meant less RDTI income, which meant a greater reliance on equity.

Funding and dilution. Shares on issue roughly doubled from 598.6m (July 2022) to 1,182.0m (June 2024). Issue prices fell from $0.025 (May 2023) to $0.021 (October 2023), $0.007 (February–March 2024) and $0.0044 (June 2024). Equity fell from $4.36m to $0.71m in two years. Cash fell to $172k at 30 June 2024 against annual operating outflows of about $5.0m, meaning the company was already reliant on shareholder loans, RDTI advances and asset sales to continue. The going-concern basis in the unaudited FY2024 report was never tested by an audit opinion, since the audit was never completed.

Inflection. The decisive inflection was June to October 2024: launch of the strategic review, termination of the SCRI grant (creating a $448k repayment obligation), failure to complete the FY2024 audit, and ASX suspension. These cut off access to public equity markets.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryOwnership FY2023Ownership FY2024Status

Bluechiip Limited (parent)

Australia

——

In liquidation since Jul 2025

Bluechiip, Inc.

United States

100%100%

Dormant; dissolution in progress (FY2024)

Bluechiip Holdings, Inc.

United States

100%100%

Dormant; dissolution in progress (FY2024)

Revenue stream (AUD K)

Revenue stream (AUD K)FY2023FY2024

Product and software licence

399.1459.1

Engineering services

425.025.6

Licence income

91.00.0

Total revenue

915.0484.7

Segment Margins & Growth (%) and Revenue by Segment (%)

Stream metrics (AUD K)FY2023FY2024

Product and software YoY growth (%)

—15.0

Engineering services YoY growth (%)

—-94.0

Product and software share of revenue (%)

43.694.7

Engineering services share of revenue (%)

46.45.3

Licence income share of revenue (%)

9.90.0

Income Statement and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024

Revenue from operating activities (AUD K)

———915.0484.7

Cost of sales (AUD K)

———206.2182.2

Gross profit (AUD K)

———708.9302.5

Other income incl. RDTI (AUD K)

———960.6885.0

Operating expenses as defined by company (AUD K)

———6,636.16,747.4

Operating income / EBIT, derived (AUD K)

———-5,010.5-5,686.5

EBITDA, company "Operating EBITDA" (AUD K)

———-4,966.6-5,559.8

Depreciation (AUD K)

———43.9126.6

Finance costs (AUD K)

———30.5126.4

Pre-tax income (AUD K)

———-5,041.0-5,812.9

Income tax (AUD K)

———0.00.0

Net income (AUD K)

———-5,041.0-5,812.9

EPS basic (A$ cents)

———-0.71-0.49

EPS diluted (A$ cents)

———-0.71-0.49

Dividends per share (A$ cents)

00000

Margin Analysis (%)

MetricFY2023FY2024

Gross margin (%)

77.562.4

Operating (EBIT) margin (%)

-547.6-1,173.2

EBITDA margin (%)

-542.8-1,147.1

Net margin (%)

-550.9-1,199.3

Revenue growth YoY (%)

—-47.0

Expense line (AUD K)

Expense line (AUD K)FY2023FY2024

Employee benefits

3,566.64,148.1

Superannuation

199.4225.5

Share-based payments

394.5320.3

Research and development (external)

650.8267.6

Patent costs

157.196.1

Travel

392.4337.8

Legal and professional fees

275.1321.6

Tradeshows, exhibitions, memberships

185.5181.9

Listing, registry, secretarial

159.6159.3

Marketing consultant

79.877.5

Advertising and branding

65.640.0

Other expenses

534.3497.0

FX gain (+) / loss (-)

24.6-74.7

Balance Sheet and Share Count (millions)

MetricFY2020FY2021FY2022FY2023FY2024

Total assets (AUD K)

———6,304.14,644.5

Cash and equivalents (AUD K)

——2,750.61,722.8172.3

Trade and other receivables incl. RDTI (AUD K)

———1,056.8889.0

Inventory, net (AUD K)

———3,218.83,299.1

Short-term borrowings, R&D advance (AUD K)

———650.0600.0

Long-term borrowings (AUD K)

———0.00.0

Lease liabilities total (AUD K)

———156.4127.7

Total debt incl. leases (AUD K)

———806.4727.7

Net debt, negative = net cash (AUD K)

———-916.4555.3

Deferred revenue (AUD K)

———2,281.02,232.4

Total equity (AUD K)

——4,362.42,364.3708.9

Goodwill and intangibles (AUD K)

00000

Working capital (AUD K)

———2,263.4555.3

Accumulated losses (AUD K)

——-43,603.1-48,644.1-54,457.0

Shares on issue (millions)

——598.6713.71,182.0

NTA per share (A$ cents)

———0.330.06

Cash Flow

MetricFY2020FY2021FY2022FY2023FY2024

Receipts from customers (AUD K)

———1,028.3476.0

Payments to suppliers and employees (AUD K)

———-6,589.3-6,422.1

RDTI received (AUD K)

——1,100.0824.8931.4

Government support programs received (AUD K)

———520.00.0

Operating cash flow (AUD K)

———-4,208.5-5,008.4

Capex (AUD K)

———-71.5-91.6

Free cash flow (AUD K)

———-4,280.0-5,100.0

Proceeds from share issues, gross (AUD K)

———2,827.54,227.1

Net borrowing flows (AUD K)

———650.0-50.0

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

Net change in cash (AUD K)

———-1,027.7-1,550.5

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024

ROE, year-end equity (%)

-213.2-820.0

ROA, year-end assets (%)

-80.0-125.2

Current ratio (x)

1.591.15

Debt / equity incl. leases (x)

0.341.03

Interest coverage, EBIT / finance costs (x)

-164.3-45.0

Asset turnover (x)

0.150.10

Inventory days on cost of sales

5,6986,609

Receivable days, trade receivables net

5967

Cash runway at FY OCF burn (months)

4.90.4

Revenue by Region

Region (AUD K)FY2023FY2024

Total

915.0484.7

Share Price and Share Count (millions)

MetricFY2022FY2023FY2024FY2025

Capital raise issue price (AUD)

—0.0250.0044—

Shares on issue at FY end (millions)

598.6713.71,182.0—

Indicative share price (AUD)

——0.0040.003

Share Price History

DatePrice (AUD)Source

June 2011 (listing)

about 0.22

CIO Australia

Aug 2019

0.145

Biotech Daily

June 2017 rights issue

0.028

ABN Newswire

May 2023 placement

0.025

June 2023 quarterly

Oct 2023 placement

0.021

FY2024 Appendix 4E

Feb–Mar 2024 placement and NREO

0.007

FY2024 Appendix 4E

May 2024 (untraded)

0.007

Biotech Daily

Jun 2024 placement

0.0044

FY2024 Appendix 4E

30 Aug 2024 (at FY2024 release)

0.004

InvestSMART

Last quoted before suspension

about 0.003

InvestSMART

Analyst Conclusions

Management guidance. None outstanding. The company is in liquidation and has no management. The last forward-looking statement before suspension aimed at cash-flow break-even through customer-base expansion and the BioLife deal driving 2025 sales. This was never achieved.

Consensus expectations. None (no coverage; delisted).

Bull case (as it stood in late 2024, now invalidated):

  1. Technology moat in a regulated niche. Electronics-free MEMS tags with per-sample cryo temperature addressed a real chain-of-identity need in CGT and IVF that barcodes and RFID handle poorly.

  2. Partner leverage. The BioLife exclusive licence (initial value up to US$750k) and the earlier FISI agreement offered capital-light global distribution.

  3. Installed-base momentum. Growth from 10 labs (FY2022) to 38 labs across 18 customers (December 2024), including three top-20 pharma customers, pointed to slow but real adoption and recurring consumables revenue.

Bear case (borne out):

  1. Unfundable burn. About $5m a year of operating cash burn against $0.5m revenue and $172k cash (June 2024) made continued dilution or failure almost certain.

  2. Commercial traction was not compounding. Revenue fell 47% in FY2024. Engineering income collapsed 94%. The OEM channel unwound (Labcon returns).

  3. Governance and reporting breakdown. Failure to complete the FY2024 audit triggered suspension, which removed the only funding channel and led to administration within six months.

Key catalysts and monitorables for the next 12 months (to October 2027):

  • Liquidator's final reports and any lodgements with ASIC on the progress of the winding-up.

  • Whether the statutory report identifies insolvent-trading or voidable-transaction claims (e.g., relating to director loans or 2024 creditor payments).

  • Identity of the asset purchaser, and whether Bluechiip MEMS technology re-emerges commercially, for example within BioLife's CGT portfolio or through a private Australian or US vehicle.

  • Formal deregistration of Bluechiip Limited by ASIC after the liquidation is completed.

  • Any shareholder tax-loss events. Shareholders may be able to claim capital losses on worthless shares under Australian tax rules; this is not advice.

Concluding analyst verdict. Bluechiip Limited is a closed case for equity investors. The shares were delisted on 28 August 2025, the business and assets were sold by the administrator in June 2025, and the liquidator has stated there will be no return to shareholders and no dividend to unsecured creditors. No investment thesis remains. The dossier's value lies in its lessons.

The company's failure was not mainly a technology failure. The MEMS tag appears to have worked as claimed, and it earned validation from Labcon, Fujifilm Irvine Scientific, BioLife Solutions and three top-20 pharma customers. The failure was in commercial model and capital structure. Over 14 listed years, Bluechiip never built revenue past about $1m a year. Its OEM-led phase ended in a settlement that returned product to its own warehouse and left a $1.8m deferred-revenue overhang. Its direct-to-market pivot then required a North American salesforce whose cost grew faster than the revenue it produced. In FY2024 operating expenses were about 14 times revenue, inventory about 6.8 times revenue, and year-end cash covered less than three weeks of burn.

The capital-markets mechanics were predictable. Each raise came at a lower price ($0.025, then $0.021, $0.007 and $0.0044), shares on issue doubled in two years, and the company slid into costly 16% R&D-advance bridging and director loans. The terminal error was operational: failing to lodge audited FY2024 accounts. That turned a distressed but listed company into a suspended one with no access to equity just as the BioLife licence arrived. A properly capitalised acquirer might yet commercialise the technology in CGT chain-of-identity, where the need is real.

Rating: Not rated. Entity in liquidation and delisted; equity value nil.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenurePrior roles and background

Iain MacGregor Crawford Kirkwood

Non-Executive Chairman and Company Secretary

Director since Nov 2007

About 35-year finance career across audit, resources, manufacturing and healthcare in Australia, the UK and the US. Started at Arthur Andersen (London); senior finance and management roles at Woodside Petroleum, Santos, Pilkington, F.H. Faulding and Clinuvel Pharmaceuticals.

Andrew McLellan

Managing Director and CEO

Since Jan 2015

Former CEO of the Advanced Manufacturing CRC (later a non-executive director there). Prior roles: Director at Leica Microsystems; VP Marketing & Business Development North America and Director of Product Management at Vision BioSystems.

Michael B. Ohanessian

Non-Executive Director

Since Dec 2014

Ten years at Mobil Oil, then Boston Consulting Group. CEO of Vision BioSystems (turned it into a profitable diagnostics business distributing to 60+ countries); Chief Executive of Genetic Technologies; investment and corporate-advisory work with Lion Capital.

Andrew Cox

Non-Executive Director

Since Jul 2017

Co-founder and former chair of Inlink (sold to oOh!media in 2015); co-founder of iPro. Early career at KPMG Melbourne, then seven years in China and Hong Kong with SG Warburg, Austrade and Ernst & Young. Member of the Murdoch Children's Research Institute translation and commercialisation committee; fluent in Mandarin.

Financial Controller (name not disclosed)

Finance

—

Hospitalisation cited as a contributor to the delayed FY2024 audit

Manuel Hanna (Romanis Cant)

Voluntary Administrator (from 17 Mar 2025), then Liquidator (from Jul 2025)

2025 to present

Insolvency practitioner

Governance Overview

AttributeAssessment

Board size

4 (3 non-executive, 1 executive)

Independence

Not formally verified. The Chair's role as Company Secretary and the directors' material shareholdings and 2024 loans compromise independence in substance.

Chair / CEO separation

Yes (Kirkwood Chair; McLellan CEO)

Committee structure

Not disclosed in sources reviewed. A four-person board implies combined or whole-board committees.

Board tenure

Long: the Chair served about 17 years by 2025; two NEDs 8–10 years

Related-party funding

Director loans totalling about $281k within roughly $996k of shareholder support (Dec 2024). Ohanessian subscribed $10k in the June 2024 placement, subject to shareholder approval.

Gender diversity

All-male board per available data

Directors' Remuneration

ItemFY2023FY2024Source

Performance rights granted to CEO (number)

4,900,0003,000,000

FY2024 Appendix 4E Note 18

Performance rights granted to employees (number)

14,500,00015,600,000

FY2024 Appendix 4E Note 18

Group share-based payment expense (AUD)

394,460320,254

FY2024 Appendix 4E Note 5

Directors' fees owing at year end (AUD)

9,16718,333

FY2024 Appendix 4E Note 13

Major Shareholders

RankHolderShares%
1

HSBC Custody Nominees (Australia) Ltd

100,834,75514.13
2

BNP Paribas Nominees (HUB24 Custodial, DRP a/c)

31,943,9304.48
3

J P Morgan Nominees Australia Pty Ltd

29,027,2714.07
4

Mutual Trust Pty Ltd

18,381,3362.58
5

Dr Stephen Frederick Woodford

18,200,0002.55
6

Iain M. C. Kirkwood (director)

15,774,9492.21
7

Allhc Pty Ltd (Sam Hupert Family a/c)

13,040,0001.83
8

Bramscorp Pty Ltd (Gilbert Family S/Fund)

8,783,1021.23
9

Edward St Consulting Pty Ltd (Kirkwood Family S/Fund)

8,320,0371.17
10

Talento Holdings Pty Ltd

7,866,6671.10

Competitive Landscape

Key Competitors

#CompetitorSegment overlapTechnologyRelative positioning
1

Thermo Fisher Scientific (Nunc, Matrix cryo consumables)

Cryovials, racks, barcoded tubes, cold storage

2D barcodes

Global consumables leader; huge channel; Bluechiip a niche alternative

2

Azenta Life Sciences (FluidX tubes, automated stores, sample management)

Biobank storage, consumables, software, services

2D barcodes; automated -80°C and cryo stores

Integrated sample-management leader

3

Corning Life Sciences

Cryovials and storage consumables

Barcodes

Scale consumables competitor

4

Greiner Bio-One

Cryo tubes and racks

Barcodes

European consumables competitor

5

Micronic

Barcoded storage tubes and racks

2D barcodes; some RFID

Specialist sample-storage vendor

6

Ziath

Rack and tube barcode readers

2D barcode imaging

Direct competitor to Bluechiip readers

7

Brady Corporation (cryo labels)

Cryogenic labelling

Printed labels and barcodes

Low-cost incumbent technology

8

Hamilton Storage

Automated sample stores

Barcode-based tracking

Automation-led tracking

9

Cryogatt Systems (UK)

Cryo RFID tracking (IVF, cell therapy)

Electronic RFID designed for cryo

Closest technology-alternative specialist

10

CooperSurgical (RI Witness)

IVF lab witnessing

RFID

Incumbent in ART traceability (overlaps the Fujifilm ART programme)

11

LIMS / biobank software vendors (e.g., LabVantage, OpenSpecimen)

Sample-management software

Software

Compete with Bluechiip Stream

Peer Comparison FY2024

MetricBluechiip FY2024Azenta FY2024BioLife Solutions CY2024Thermo Fisher CY2024

Revenue (local currency, millions)

0.48 (AUD)

about 656 (USD)

about 82 (USD)

about 42,900 (USD)

Revenue growth YoY (%)

-47.0——

about 0

Gross margin (%)

62.4———

EBITDA margin (%)

-1,147.1———

R&D intensity (% of revenue)

55.2 (external R&D only)

——

about 3

Recent Developments

The company has produced no news since about October 2025, when the liquidator's statutory report was due. Entries are in chronological order.

Company Snapshot

2003

Founded

Scoresby, Australia

Headquarters

SWOT Analysis

Strengths

  • Differentiated, patented core technology: Electronics-free MEMS tag; claimed -196°C to +200°C operation; tolerant of autoclave, gamma and centrifuge (ASX boilerplate, 2017–2024)
  • Unique per-sample temperature with ID in cryo: Management described it as the only cryo system with temperature plus ID (ASX releases; Business News Australia, Mar 2025)
  • Blue-chip customer validation: Orders from three global top-20 pharma companies by Nov 2023 (MT Newswires)
  • Credible OEM partners: Labcon (FY2019), Fujifilm Irvine Scientific (Oct 2021), BioLife Solutions (Dec quarter 2024; up to US$750k initial value)
  • Growing installed base: 10 labs (FY2022), 26 labs and 14 end-users (Jun 2023), 38 labs and 18 customers (Dec 2024)
  • High product gross margin: Gross margin 77.5% (FY2023) and 62.4% (FY2024) (FY2024 Appendix 4E)
  • Access to non-dilutive R&D funding: RDTI cash of $1.1m (FY2021 claim), $825k (FY2023 cash), $931k (FY2024 cash)

Weaknesses

  • Sub-scale and shrinking revenue: $1.025m (FY2019) to $485k (FY2024); 5-year CAGR about -13.9%
  • Cost base about 14 times revenue: Operating expenses $6.75m against revenue $0.48m (FY2024)
  • Chronic cash burn and thin liquidity: OCF -$5.01m; year-end cash $172k (FY2024)
  • Excess, aged inventory: $3.30m inventory, about 6.8 times revenue, including returned Labcon stock (Note 11 and Note 16)
  • Severe dilution and falling issue prices: Shares 598.6m to 1,182.0m in two years; issue price $0.025 to $0.0044
  • Governance and reporting failures: Failed to lodge FY2024 audited accounts, leading to the Oct 2024 suspension (ASX)
  • Expensive bridge debt: RDTI advance at 16% p.a.; finance costs up four times to $126k (FY2024)

Opportunities

  • CGT chain-of-identity demand: BioLife licence targeted CGT packaging; BioLife reported its media embedded in growing numbers of approved CGTs (BioLife SEC 8-K, 2024)
  • IVF / ART market: More than 2.5m IVF cycles a year cited by management; FISI development agreement
  • Recurring consumables and software: Q4 FY2023 recurring revenue about $75k, triple Q2 FY2023
  • European expansion: UK distribution (Biopharma Process Systems), Jun 2024
  • Strategic sale to a larger player: Cogent-led review aimed at North American and European parties (Jun 2024)
  • Workflow integration products: Bluechiip Workstation launched Jun 2024

Threats

  • Funding-market closure: Suspension 1 Oct 2024; ASX LR 12.2 inadequacy finding; delisted 28 Aug 2025
  • Incumbent barcode and RFID ecosystems: Thermo Fisher, Azenta and Corning bundle consumables, automation and software
  • OEM partner concentration and failure: Labcon settlement with full product return; engineering revenue down 94% in FY2024
  • US macro and biotech funding cycle: Management cited adverse US conditions for the FY2024 decline
  • Government grant clawback: SCRI refund of $448k invoiced Jul 2024
  • Partner strategic shifts: FISI sold its IVF medical media unit to Astorg (Jan 2025), creating uncertainty for the ART programme
  • Supplier-continuity concerns from customers: Insolvency in Mar 2025 crystallised this risk

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Jul 2023Q4 FY2023 report: sales $171k; $2.9m raised; recurring revenue in Q4 triple Q2; cash $1.723m, borrowings $650kPeak of commercial momentum
Oct 2023Placement of $1.732m at $0.021Funding for North America push
25 Oct 2023Regal Funds becomes substantial holder (5.57%)Brief institutional endorsement
9 Nov 2023Order from a third global top-20 pharma companyCustomer validation
29 Nov 2023$931k FY2023 RDTI refund securedNon-dilutive funding
30 Nov 2023AGM presentationStrategy update
12 Dec 2023Regal Funds ceases to be substantial holderInstitutional exit
5 Feb 2024Up to about $4.8m equity raising announcedLarge discounted raise
Feb 2024Placement of $835k at $0.007Price reset of about 67% versus October 2023
12 Mar 2024Entitlement offer results: $1.303m raisedUndersubscription versus the $4.8m target (implied)
21 May 2024CEO interview: direct-to-market strategy; latest quarter very lightAdmission of weak trading
Jun 2024Strategic review launched; Cogent Venture Partners engagedSignals sale or partner search
12 Jun 2024Placement of $367.6k at $0.0044 for working capital during the reviewDistressed funding
Jun 2024Bluechiip Workstation launched at BIO International, San DiegoProduct launch
Jun 2024 quarterUK distribution deal (Biopharma Process Systems); North American pharma expansion orderCommercial progress
24 Jun 2024SCRI grant mutually terminatedCreates a repayment liability
30 Jul 2024DISR invoices $448,110 (incl. GST) for grant refundAdds to cash strain
31 Jul 2024Q4 FY2024 report: sales $116k; customer receipts $58k; $300k shareholder loanVery low cash receipts
29 Aug 2024EGM approves up to $3m capacity (shares and convertible notes)Funding optionality
30 Aug 2024Unaudited FY2024 Appendix 4E: revenue $485k (-47%); loss $5.81m; cash $172kLast published accounts
Late Sep 2024Trading halt; announced delay in audited FY2024 accountsPrecursor to suspension
1 Oct 2024ASX suspension for non-lodgementLoss of market access
Q4 CY2024BioLife Solutions exclusive licence; initial project value up to US$750kBest partnership; came too late
Dec 2024About $996k shareholder support incl. $281k director loansLast-ditch funding
Early 2025ASX: financial condition inadequate (LR 12.2); suspension continuesReinstatement blocked
17 Mar 2025Voluntary administrator appointed (Manuel Hanna, Romanis Cant)Insolvency
18 Mar 2025ASX Settlement suspends CHESS approvalRegistry frozen
27 Mar 2025First creditors' meetingInsolvency process
Mar–Jun 2025National sale and recapitalisation campaign by the administratorSale process
17 Jun 2025Offer for assets accepted; no DOCABusiness sold
Jul 2025Creditors resolve to wind up; liquidator appointed; update lodged 4 Jul 2025No return to shareholders or unsecured creditors
28 Aug 2025Removed from ASX Official ListDelisting
4 Sep 2025CHESS subregister closedFinal market step
By 3 Oct 2025Liquidator's statutory report due–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operating activities fell from AUD 0.9 Mn in FY2023 to AUD 0.5 Mn in FY2024.
Bluechiip Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2023FY2024
Revenue from operating activities0.90.5
Cost of sales0.20.2
Gross profit0.70.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Bluechiip Limited, Appendix 4E Preliminary Final Report for the year ended 30 June 2024 (unaudited), ASX, 30 Aug 2024 (announcements.asx.com.au)
  2. Bluechiip Limited, Equity Raising of up to about $4.8m, ASX, 5 Feb 2024 (announcements.asx.com.au)
  3. Bluechiip Limited, Placement completion, ASX, 12 Jun 2024 (announcements.asx.com.au)
  4. Bluechiip Limited, June 2023 Quarterly Cash Flow Report, ASX, 28 Jul 2023 (announcements.asx.com.au)
  5. Bluechiip Limited, $1.1m R&D Tax Incentive Refund, ASX, 29 Jun 2022 (announcements.asx.com.au)
  6. Bluechiip Limited, 2023 AGM presentation, ASX, 30 Nov 2023 (announcements.asx.com.au)
  7. ASX Compliance, Removal from Official List, 29 Aug 2025 (announcements.asx.com.au)
  8. ASX Online Notice 0263.25.03, Suspension of Approval (Voluntary Administrator Appointed), 18 Mar 2025 (asxonline.com)
  9. ASX Online Notice 1036.25.09, Cessation of approval, 5 Sep 2025 (asxonline.com)
  10. Business News Australia, Bluechiip appoints administrator after declaring insolvency, Mar 2025 (businessnewsaustralia.com)
  11. TipRanks, Bluechiip Limited Finalizes Asset Sale and Enters Liquidation, 2025 (tipranks.com)
  12. TipRanks, Bluechiip Limited Faces Continued Suspension on ASX (tipranks.com)
  13. TipRanks, Bluechiip Advances Strategic Moves Amidst Trading Halt, 2024 (tipranks.com)
  14. TipRanks, Shares Remain Suspended Amid Strategic Review and New Developments (tipranks.com)
  15. TipRanks, Strategic Moves and Financial Update for December 2024 (tipranks.com)
  16. TipRanks, Bluechiip Partners with BioLife for CGT Market Expansion (tipranks.com)
  17. TipRanks, Bluechiip Limited Faces Substantial Financial Decline (tipranks.com)
  18. Market Index, BCT company page and announcements (marketindex.com.au)
  19. Market Index, Update on Liquidation, 4 Jul 2025 (marketindex.com.au)
  20. Motley Fool Australia, Bluechiip (ASX: BCT) ticker page (directors, top shareholders via Morningstar) (fool.com.au)
  21. Morningstar Australia, Bluechiip Ltd company profile (morningstar.com.au)
  22. InvestSMART, BCT price-sensitive announcement summaries (Jul and Aug 2024): and: investsmart.com.au · investsmart.com.au
  23. moomoo / MT Newswires, BCT news headlines 2023–2024 (moomoo.com)
  24. Stockhead, Bluechiip jumps on licence and development deal with Fujifilm Irvine Scientific, Oct 2021 (stockhead.com.au)
  25. Biotech Daily, 21 May 2024 edition (biotechdaily.com.au)
  26. BioMelbourne / Biotech Daily, Bluechiip revenue for FY19 up 82.5%, Aug 2019 (biomelbourne.org)
  27. CIO Australia, Bluechiip posts $3.6m FY11 loss (www2.cio.com.au)
  28. BioSpace / ABN Newswire, Bluechiip raises $3.425m from rights issue and placement, Jul 2017 (biospace.com)
  29. EE World Online, Sofcom / Bluechiip merger (historical) (eeworldonline.com)
  30. Eulerpool, Bluechiip (ISIN AU000000BCT7) (eulerpool.com)
  31. trading-treff.de, Bluechiip shareholders' total loss confirmed (trading-treff.de)
  32. BioLife Solutions, Form 8-K earnings releases 2024 (SEC) (sec.gov)
  33. Business Wire, FUJIFILM Irvine Scientific sells Medical Media Business to Astorg, Jan 2025 (businesswire.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.